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Abstract
Introduction Lymphedema can be a debilitating condition,
causing a great decrease in a person’s quality of life (QoL).
Treatment with lymphaticovenular anastomosis (LVA), in
which an anastomosis is created between the lymphatic and
venous system, may attenuate lymphedema symptoms and
reduce swelling. In this study, we share the results using
LVA to treat breast cancer-related lymphedema (BCRL) at
our institution.
Materials and methods Patients were eligible for inclusion
if they suffered from unilateral BCRL, if functional lym-
phatics were available, if compression therapy was used for
at least 6 months, and if the follow-up was 12 months at
minimum. Lymph vessel functionality was assessed pre-
operatively using indocyanine green (ICG). During sur-
gery, 1–3 anastomoses were created and shunt patency was
confirmed using ICG. Arm volumes were measured before
surgery and at 6- and 12-month follow-up. QoL was
measured before surgery and at 6-month follow-up. Arm
volume differences between the healthy arm and affected
arm were compared between the time points.
Results Twenty-nine consecutive female patients with
unilateral BCRL were included. The preoperative mean
difference in arm volumes was 701 ± 435 ml (36.9%).
This was reduced to 496 ± 302 ml (24.7%) at 6-month
follow-up (p = 0.00). At 12-month follow-up, the mean
difference in arm volume was 467 ± 303 ml (23.5%)
(p = 0.02). The overall perceived QoL was increased from
5.8 ± 1.1 to 7.4 ± 0.7 (p = 0.00). The functionality score
decreased from 2.2 to 1.8 (p = 0.00), the appearance score
decreased from 2.6 to 1.9 (p = 0.00), the symptoms score
decreased from 2.8 to 1.8 (p = 0.00), and the mood score
decreased from 2.7 to 1.5 (p = 0.00). Fifteen patients
(53.6%) were able to discontinue the use of compression
garment.
Conclusion Treatment with LVAs is effective in reducing
arm volume difference in patients suffering from BCRL.
Although no complete reduction of the edema was
achieved at 12-month follow-up, the procedure signifi-
cantly increased the patients’ QoL.
Keywords Lymphaticovenular anastomosis 
Lymphedema surgery  Lymphedema treatment
Introduction
Lymphedema can be a debilitating condition, causing pain,
body image disturbances, frequent infections, restrictions
in range of motion, and a great decrease in a person’s
quality of life (QoL) [1]. Axillary lymph node dissection,
radiation therapy to the axillary region, postoperative ser-
oma in the axillary region, and obesity are major risk
factors for the development of lymph edema [2]. Reports
on the incidence of lymphedema following breast cancer
treatment vary widely with 24–49% following mastec-
tomies and 4–28% following breast conserving therapy [3].
When the swelling of a lymphedematous extremity is due
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to excess fluid, like in the earlier stages of lymphedema
progression, pitting edema can be observed. When the
excess volume is due to adipose or fibrous tissue, pitting
edema will be minimal or absent [4].
Treatment of lymphedema consists of both non-opera-
tive and operative methods [5]. Conservative treatment is
currently considered to be the standard of care. This
includes lymphatic-specific massage techniques, exercise,
and external compression. The goal of the treatment is to
manually compress tissue and to remove the retained
interstitial fluid [6]. After this, the fitted garments are
required to prevent the re-accumulation of fluid. However,
this therapy is primarily aimed at delaying progression and
is not curative [7].
Surgical treatments for lymphedema mainly focus on
excisional and reconstructive techniques. Excisional sur-
gery includes debulking and liposuction [8]. Reconstruc-
tive options include lymphaticovenular anastomosis
(LVA), lymphovenous-lymphatic (LVL) transplant, lym-
phatic vessel transplantation, and vascularized lymph node
transfer (VLNT). [3, 9–11]. Currently, reconstructive
options are considered to be more effective in early-stage
‘pitting’ lymphedema due to the progressive nature of this
condition. In later stages, when there is non-pitting lym-
phedema, reconstructive options may not be viable due to
the absence of functional lymphatics [12].
Using LVA, the lymph fluid in the extremity affected by
lymphedema can bypass the natural route of traveling
through lymph vessels to the subclavian veins and entering
the bloodstream. This technique was first described in 1963
by Laine and Howard in a rat model [13]. In 1969, Yamada
performed studies on LVA in dogs. Several other authors
have, since then, improved this procedure so it could be
utilized in the treatment of lymphedema in humans [9]. To
allow for lymphatic fluid to enter the venous blood stream
through a LVA, it is important that the pressure in the
lymphatic system is higher than the pressure in the recip-
ient vein. Since there may be a lower pressure in smaller
venules compared to larger veins, utilizing small venules as
recipient vessels might lower the risk of occlusion of the
LVA due to venous backflow [14–16].
With the availability of superfine monofilament sutures
and, more recently, indocyanine green (ICG) lymphogra-
phy, performing LVAs on small subdermal venules and
functional lymphatic collectors as small as 0.3 mm has
become a practical reality. Recently, promising results
regarding lymphedema volume reduction are emerging
[17–19]. In addition, previous research demonstrates a
significant increase in QoL in patients suffering from
BCRL when treated with LVA [20]. In this study, we share
the preliminary results using LVA to treat breast cancer-
related lymphedema (BCRL) at our institution.
Patients and methods
Patients
Patients were eligible for inclusion if they suffered from
unilateral BCRL, if functional lymphatics were available, if
compression therapy was used for at least 6 months, and if
the follow-up was 12 months at minimum. Lymphedema
was defined as a volume increase of C10% compared to the
non-affected arm or self-reported heaviness or swelling,
which is the commonly used definition of lymphedema
[21]. No limits were set on the duration of the lym-
phedema. The lymphedema was staged with Campisi’s
lymphedema classification [22]. Patient characteristics and
baseline volume measurements were noted in a pre-defined
form. Lymphatic functionality was evaluated preopera-
tively using ICG lymphography. For this technique, ICG
(0.5%, 0.5 ml, Diagnogreen, Daiichi Pharmaceutical,
Tokyo, Japan) was injected subcutaneously in the 2nd
webspace of the hand. A photodynamic eye (PDE) was
used to identify lymph vessels. Lymphatics were consid-
ered functional if ICG lymphography demonstrated a linear
Fig. 1 Linear pattern demonstrated by ICG lymphography in a
patient with BCRL. This pattern indicates that the lymphatics possess
contractility
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pattern according to the Yamamoto ICG staging system
(Fig. 1) [23].
Surgical Technique
Surgery was performed by two experienced plastic sur-
geons under general anesthesia. Lymphaticovenular anas-
tomoses were performed through 3–4 cm incisions at the
distal wrist or forearm in the lymphedematous extremity
using a surgical microscope (ZEISS OPMI 800; 925 to
950 magnification). The subdermal region was dissected to
identify lymphatic vessels of 0.3–0.8 mm in diameter. This
was achieved by using ICG lymphography intraopera-
tively. Similarly sized adjacent venules were explored to
anastomose the vessels and create the LVA. LVAs were
generally performed end-to-end using 11-0 nylon sutures.
If the recipients’ veins were substantially larger, end-to-
side anastomoses were performed. Patency of the newly
formed anastomosis was confirmed intraoperatively by
ICG lymphography. Patients were given a prophylactic
antibiotic intraoperatively and for 5 days postoperatively.
All patients were discharged within 24 h. After surgery, the
affected arm was wrapped with a special compression
bandage (Rosidal TCS, Lohmann & Rauscher, Germany)
for 1 week and elevated on a pillow. One week after sur-
gery, patients started to continue previous compression
therapy which included the usage of compression arm
sleeves. After 6 months, the possibility to discontinue
compression stockings was evaluated on patient request.
Outcomes
All data were collected according to a standardized pro-
tocol at our institution. Therefore, volume measurements
and QoL scores were available for each patient at pre-
determined time points. The outcomes were collected
during chart review in a retrospective fashion.
The primary outcome was the percentage reduction in
volume difference between the affected and the healthy
arm. Volume measurements of both the lymphedema and
healthy extremity were performed using the water dis-
placement technique preoperatively and at 6-, and
12-month follow-up. All measurements were performed by
an experienced physiotherapist (CB) using a standardized
volumeter and lukewarm water. Previous research indicates
that water temperatures varying between 20 and 32 do
not affect arm volume [24].
Secondary outcomes were as follows: the change in QoL
after 6 months of follow-up, the possibility to discontinue
compression garment usage after 6 months of follow-up,
and the relation between decrease in volume difference
between extremities and the volume decrease of the
affected extremity. QoL was measured preoperatively and
6 months after LVA surgery using the LymphQoL arm
questionnaire, a validated questionnaire for patients with
lymphedema of the arm to determine QoL [25]. In this
questionnaire, patients rated their overall QoL (range 1–10)
in addition to subdomains regarding functionality,
appearance, symptoms, and patients mood (range 1–4). The
effect of the affected extremity on these subdomains was
scored from one to four. One indicating the swollen
extremity affected the QoL in this domain not at all, two a
little, three quite a lot and four a lot. An increase in the
overall QoL reflects a positive change in the QoL, while a
decrease in the subdomains indicates that the subdomain is
less affected by the lymphedema. Furthermore, the rela-
tions between the preoperative variables, i.e., difference in
arm volumes, BMI, and volume difference reduction and
increase of QoL, were explored.
Statistical analysis
Paired student t-tests were used to compare the volume
changes between the affected and the healthy extremity
before surgery, 6 months of follow-up, and 12 months of
follow-up. Then the percentage decrease in arm volume
difference was calculated. In addition, paired student t-tests
were used to compare the LymohQoL arm questionnaire
results before surgery and after 6 months of follow-up.
A Pearson’s correlation analysis was performed to deter-
mine the correlation between the decrease in volume dif-
ference between arms and the decrease in volume of the
affected arm only. Correlations between the percentage
arm volume difference decrease after 12 months and arm
volume difference at baseline, BMI, duration of edema, and
number of anastomoses created were calculated.
The increase in QoL was defined as minor or major
improvement. Minor improvement was defined as one
point increase in the QoL. Major improvement was defined
as[2 point increase in the QoL. Then student t-tests were
performed to detect differences between minor and major
QoL for the variables: arm volume difference at baseline,
BMI, duration of edema, and number of anastomoses cre-
ated. When a significant difference of means was detected,
a binary logistic regression was performed to determine the
odds for major QoL improvement. All analyses were per-
formed with IBM SPSS version 22 (IBM Corp., Armonk,
N.Y.).
Results
Twenty-nine consecutive female patients with unilateral
BCRL were eligible for inclusion. Patient characteristics
are listed in Table 1. The mean age of these patients was
59 ± 9 years (range 41–84 years). Their BMI was
Breast Cancer Res Treat (2017) 165:321–327 323
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27 ± 4 kg/m2 (range 21–34). Twelve patients had lym-
phedema in their left arm and 17 in their right arm. Three
of the treated patients had less than 10% volume surplus
but experienced complaints because of the edema
nonetheless. All patients demonstrated pitting lymphedema
(stage 1b–2a according to Campisi). Lymphedema was
present for a mean period of 9 ± 7.3 years (range
2–39 years). All patients gave informed consent regarding
the surgical procedure and ICG injection.
The mean number of anastomoses was 1.8 ± 0.8 (range
1–3). Ten patients received 1 LVA, 14 patients two LVAs,
and five patients three LVAs. The anastomoses were most
commonly performed end-to-end (n = 45), followed by
end-to-side (n = 6), and the invagination technique
(n = 2). The diameter of the lymphatic vessels used for
bypass ranged from 0.3 to 0.7 mm. The mean operative
time was 2.8 ± 0.4 h. No postoperative complications,
defined as complication occurring within 30 days after
surgery, occurred. During follow-up, two patients endured
two episodes of cellulitis.
Volume measurements
The preoperative mean difference in arm volume was
701 ± 435 ml. This was reduced to 496 ± 302 ml at
6-month follow-up (p\ 0.001). At 12-month follow-up,
the mean difference in arm volume was 467 ± 303 ml
(23.5%) (p\ 0.001) (Fig. 2). Therefore, the percentage
volume reductions at 6- and 12-month follow-up were 29
and 33%, respectively. Of the 29 patients, 28 patients
treated with LVA showed an improvement of the volume
difference between arms. The volumetric arm difference
increased in one patient. When the decrease of arm volume
difference between the affected and the healthy extremity
was compared to the decrease of volume of the affected
extremity only, the correlation was r = 0.60 (p = 0.00)
There was no significant correlation between the volume
difference reduction between arms and the variables: arm
volume difference at baseline (r = -0.15, p = 0.44), BMI
(r = -0.06, p = 0.52), duration of edema (r = -0.15,
p = 0.45), number of anastomoses created (r = -0.03,
p = 0.89).
Quality of life
The overall perceived QoL was increased from 5.8 ± 1.1
to 7.4 ± 0.7 (p = 0.00). The functionality score decreased
from 2.2 to 1.8 (p = 0.00), the appearance score decreased
from 2.6 to 1.9 (p = 0.00), the symptoms score decreased
from 2.8 to 1.8 (p = 0.00), and the mood score decreased
from 2.7 to 1.5 (p = 0.00) (Fig. 3). Fifteen patients
(53.6%) were able to discontinue the use of compression
garment.
Considering minor versus major improvement in QoL,
only the arm volume difference at baseline was significantly
higher in the major QoL improvement group. Arm volume
difference at baseline was 473 ml in the minor improve-
ment group and 907 ml in the major improvement group
(p = 0.007). The mean BMI was 25.8 in the minor
improvement group and 28.6 in the major improvement
group (p = 0.06). Mean duration of edema was 10.3 years
in the minor improvement group and 8.07 years in the
major improvement group (p = 0.45). The mean amount of
anastomoses created was 2.08 in the minor improvement
group and 1.60 in the major improvement group (p = 0.08).
The variable arm volume difference at baseline was
categorized in groups in which the arm volume difference
was increased by 250 ml each step. Then a binary logistic
regression analysis was performed. The odds ratio (OR) to
a major increase in QoL was 2.06 (p = 0.02,
CI = 1.10–3.86) per 250 ml.
Table 1 Patient characteristics
Patient characteristic N (%)
Age, years, mean (range) 57 (25–84)
BMI, kg/m2, median (range) 26 (23–34)
Lymph edema duration, mean (range) 9 (2–39)
Right extremity 16 (59)
Anastomoses 53 (100)
End-to-end 45 (84)
End-to-side 6 (12)
Invagination 2 (4)
Number of anastomosis, mean (range) 1.8 (1–3)
Operative time, min, mean 168
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Fig. 2 Average volume differences between the healthy and affected
extremity at different time points during follow-up. Error bars
indicate standard deviation (SD). Significance was reached between
baseline and 6 months of follow-up (p\ 0.001), between baseline
and 12 months of follow-up (p\ 0.001), and between 6 months of
follow-up and 12 months of follow-up (p\ 0.02)
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Discussion
Although LVA was considered a controversial technique in
the treatment of lymphedema, it is gaining popularity with
the advancement of microsurgical techniques. Previous
studies demonstrate mixed results following the LVA
procedures, but the quality of these studies vary. In addi-
tion, most studies evaluating LVA present the results in
primary and secondary lymphedema of both the upper and
lower extremities as one, while the effect of LVA most
likely differs per lymphedema modality [26, 27].
This study demonstrates the results of LVA surgery in
secondary lymphedema resulting from breast cancer treat-
ment. To our knowledge, this study is the first to assess the
effects of LVA on the QoL of BCRL patients who expe-
rienced significant volume reduction between arms. In
addition, although in a relatively small population, it is the
first time the relation between preoperative variables and
outcomes is explored.
For this study, only patients with unilateral BRCL were
included. This allowed for the unaffected arm to be used as
inpatient control. Patients included in this study experi-
enced a reduction of 33% of the arm volume difference at
12-month follow-up. In one patient, the volume difference
between arms increased, but the QoL increased too. The
QoL of patients increased in all but one patient. In this
patient, there was a volume decrease between arms. The
preoperative arm volume difference proved to be a sig-
nificant predictor to a greater increase of QoL. Interest-
ingly, the decrease in arm volume difference between arms
was not larger in patients who experienced a greater
increase in QoL. In this study, the possible volume effect of
arm dominancy was not taken into account.
In our study population, the patients’ BMI, the amount
of shunts created, and the duration of the edema did not
affect the effect of the procedure on volume reduction
between arms or QoL. While the QoL was increased in the
majority of patients after 6 months, it is likely that the QoL
was further increased after 6 months due to the great
amount of patients that were able to discontinue the use of
compression garment.
Since lymphedema surgery is considered controversial
in the Netherlands and its place in the treatment of lym-
phedema is still unconfirmed, we were very cautious con-
cerning the discontinuation of compression garments. In
the population studied in this paper, patients came with the
request to discontinue compression therapy when they
noticed attenuation of their complaints. Only then, we
advised to slowly phase the discontinuation of compression
garments by increasing the time spent without compression
garments. Then, if arm volume remained stable or
decreased, and the patient noticed no subjective increase of
the lymphedema, the compression therapy could be fully
discontinued. For all patients, we strongly encouraged the
use of compression therapy until minimally 6 months after
surgery.
The results demonstrated in this study are in line with
recent trials evaluating LVAs in secondary upper limb
lymphedema patients. Chang et al. reported that arm vol-
umes decreased in 74% of patients with upper limb lym-
phedema, and these patients experienced a volume
reduction of 42% of the affected limb [28]. Poumellec et al.
found a volume reduction of 22.5, 21.32, and 30.24% in the
affected wrist, forearm, and arm, respectively [29]. In our
study, the effect of LVAs was determined by comparing
the volume differences between the affected and the
healthy arm between time points, instead of comparing the
difference in volume of the affected arm only. This ensures
that the measured results are not affected by variables such
as air humidity and temperature and therefore reflects a
2.2
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Fig. 3 Mean reduction and
standard error (SE) of the
LYMQOL-arm index score
regarding the subdomains. A
lower score in the subdomains
indicates that patients were less
affected by the lymphedema in
that subdomain
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more precise effect of the procedure. This is underlined by
the low correlation between decrease of volume of the
affected arm and the decrease of volume difference
between arms found in this study (r = 0.60).
Volume measurements of both the lymphedematous and
healthy extremity were performed using a water displace-
ment technique. This technique is highly accurate in
measuring arm volume with an intraclass correlation
coefficient (ICC) of 0.99 [30, 31]. More recently, we
however started measuring lymphedema volumes with 3D
stereo photogrammetry in our institution. This may mea-
sure lymphedema volumes more accurate and may become
the first choice diagnostic tool for lymphedema volume
assessment [32–34]. The effect of limb dominance on arm
volume is known to be statistically significant but small
and was not taken into account in this study [35].
Concerning the peri-operative care for lymphati-
covenular anastomosis, a protocol was followed based on
several recommendations in the current literature. It is
however imperative to note that these recommendations are
solely based on expert opinions and no evidence is avail-
able to support these suggestions. Animal studies indicate
that the long-term patency of LVAs can be as low as 52%.
Therefore, it is of great importance to optimize the peri-
operative conditions to improve the shunt patency. As it is
currently unknown if peri-operative interventions such as
compression therapy directly post-surgery may either harm
or benefit the patency, future studies should clearly state
the peri-operative care that was used. Then it may become
possible to optimize the effect of LVA.
Although the results of this study were analyzed in
retrospect, data were collected according to a standardized
protocol at our institution. Therefore, data concerning arm
volumes were available for each patient at pre-determined
times during follow-up. In addition, preoperative variables
such as ICG lymphography and duration of the lym-
phedema were also noted for each patient. To ensure that
all anastomoses were patent directly post-surgery, ICG
lymphography was used during surgery.
Conclusion
Treatment of BRCL with LVA seems an effective strategy
in reducing the volume difference between arms and
increasing the patients QoL. Interestingly, the reduction in
volume differences was not correlated to a greater increase
in QoL. In addition, the amount of shunts created, patients
BMI, and the lymphedema duration did not affect volume
reduction or the patients QoL. Future research, most
preferably in a randomized controlled fashion, should
confirm these findings.
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